RT Journal Article
SR Electronic
T1 SPLUNC1: A Novel Marker of Cystic Fibrosis Exacerbations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.15.20100669
DO 10.1101/2020.05.15.20100669
A1 Sara Khanal
A1 Megan Webster
A1 Naiqian Niu
A1 Myra Nunez
A1 Geoffrey Chupp
A1 Martin D. Slade
A1 Lauren Cohn
A1 Maor Sauler
A1 Jose L. Gomez
A1 Robert Tarran
A1 Lokesh Sharma
A1 Charles S. Dela Cruz
A1 Marie Egan
A1 Theresa Laguna
A1 Clemente J. Britto
YR 2020
UL http://medrxiv.org/content/early/2020/05/19/2020.05.15.20100669.abstract
AB Acute pulmonary Exacerbations (AE) are episodes of clinical worsening in cystic fibrosis (CF), often precipitated by infection. Timely detection is critical to minimize the morbidity and lung function decline associated with acute inflammation during AE. We previously demonstrated that the airway protein Short Palate Lung Nasal epithelium Clone 1 (SPLUNC1) is regulated by inflammatory signals. Here, we investigated the use of SPLUNC1 fluctuations to diagnose and predict AE in CF.We enrolled adult CF subjects from two independent cohorts to measure AE markers of inflammation in sputum and recorded clinical outcomes for a 1-year follow-up period.SPLUNC1 levels were high in healthy control sputum (n=9, 10.7μg/mL), and significantly decreased in CF subjects without AE (n=30, 5.7μg/mL, p=0.016). SPLUNC1 levels were 71.9% lower during AE (n=14, 1.6μg/mL, p=0.0034) regardless of age, sex, CF-causing mutation, or microbiology findings. Cytokines Il–1β and TNFα were also increased in AE,whereas lung function did not consistently decrease. Stable CF subjects with lower SPLUNC1 levels were much more likely to have an AE at 60 days (Hazard Ratio: 11.49, Standard Error: 0.83, p=0.0033). Low-SPLUNC1 stable subjects remained at higher AE risk even one year after sputum collection (Hazard Ratio: 3.21, Standard Error: 0.47,p=0.0125). SPLUNC1 was transcriptionally downregulated by inflammatory cytokines and degraded by proteases increased in sputum during AE.Our findings suggest that low sputum SPLUNC1 levels could detect subjects at increased risk of AE in order to guide early therapeutic interventions in CF.TAKE-HOME MESSAGE Sputum concentrations of the secreted airway protein SPLUNC1 decrease during CF exacerbations. Lower SPLUNC1 levels in stable subjects portend a significantly increased risk of exacerbation and could inform therapeutic interventions.PLAIN LANGUAGE SUMMARY SPLUNC1 is an abundant host defense protein found in the respiratory tract that decreases with inflammation. Individuals with cystic fibrosis experiencing clinical worsening (exacerbation) have much lower levels of SPLUNC1 in their sputum. In stable cystic fibrosis patients, lower levels of SPLUNC1 may predict an upcoming respiratory illness. Therefore, SPLUNC1 may serve as a tool for early diagnosis and treatment of cystic fibrosis exacerbations.Competing Interest Statement-Dr. Tarran reports: from Eldec Pharmaceuticals, outside the submitted work; In addition, Dr. Tarran has a patent Peptide inhibitors of Ca2+ channels pending, a patent PEPTIDE INHIBITORS OF SODIUM CHANNELS with royalties paid, and a patent Regulation of sodium channels by PLUNC proteins with royalties paid. -Dr. Laguna reports grants from National Institutes of Health, grants from Cystic Fibrosis Foundation, other from Vertex Physician Advisory Board, outside the submitted work;. -Dr. Cohn reports other from Genentech, other from Novartis, other from Astra-zeneca, other from GlaxoSmithKline, other from Regeneron, other from Pieris, other from Sanofi, outside the submitted work;. -Dr. Chupp reports from Genentech, other from Astra Zeneca, other from Sanofi - Regeneron, other from GSK, other from TEVA, other from Boehringer-Ingelheim, other from Circassia, outside the submitted work;.Clinical TrialOur study is not registered as a clinical trial because this is an observational study. We are not testing potential treatments for Cystic Fibrosis (CF), rather we are developing clinical markers to identify people at risk of clinical worsening in CF.Funding StatementThis work was supported by NIH R01-HL081160 and R21-AI083475 (LC), NIH T32-HL007778, NIH/NHLBI K01-HL125514-01, and Cystic Fibrosis Foundation’s Fifth Year Clinical Fellowship (CB), American Thoracic Society Foundation Unrestricted Research Award (CB), CF Foundation (RT); UK CF Trust (RT).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata